CTOs on the Move

Sorrento Therapeutics

www.sorrentotherapeutics.com

 
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento recently announced that NantPharma acquired the rights to Cynviloq™, which completed a successful TRIBECA study. Sorrento is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. In December 2014, Sorrento and NantWorks formed a global joint venture, now called Nantibody, to focus on immunotherapies for cancer. Also in December 2014, Sorrento and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast,® a Natural Killer (NK) cell-line based therapy, entered into ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Sorrento Therapeutics raised $150M on 04/11/2016
Sorrento Therapeutics raised $25M on 10/09/2019

Similar Companies

Martek Biosciences Corporation

Martek Biosciences Corporation is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Armata Pharmaceuticals

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.

Terumo Heart

Terumo Heart, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BreakBio

BreakBio Corp is a biotechnology company focused on breakthrough cancer treatment and prevention. They use their proprietary AI platform to find multiple proteins on each patients cancer cells and custom manufacture drugs for each patient. Their goal ...

Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing first-in-class targeted agents to treat life-threatening cancers.